According to GlobalData’s medical device pipeline database, 51 Specific Proteins devices are in various stages of development globally. GlobalData’s report Specific Proteins provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 12 are in active development, while the remaining 40 are in an inactive stage of development. There are eight products in the early stages of development, and the remaining four are in the late stages of development.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Specific Proteins pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Specific Proteins devices. Overall, most of these Specific Proteins pipeline devices are being developed by private entities.
Key players involved in the active development of Specific Proteins include Beckman Coulter, Roche Diagnostics International, Siemens Healthcare Diagnostics, SomaLogic, Alfa Wassermann Diagnostic Technologies, Amerimmune, Ortho Clinical Diagnostics, Ottawa Hospital Research Institute, Roche Diagnostics and Sunbird Bio.
For a complete picture of the developmental pipeline for Specific Proteins devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.